Suppr超能文献

墨西哥一项前瞻性队列研究:大流行期间放化疗病房中癌症患者和医护人员的 SARS-CoV-2 感染率。

SARS-CoV-2 Infection Rate in Patients With Cancer and Health Care Workers in a Chemoradiotherapy Unit During the Pandemic: A Prospective Cohort in Mexico.

机构信息

Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Facultad de Medicina, Universidad Autónoma de Coahuila Unidad Torreón, Torreón, México.

出版信息

JCO Glob Oncol. 2021 Sep;7:1639-1646. doi: 10.1200/GO.21.00207.

Abstract

PURPOSE

Cancer treatment during the COVID-19 pandemic represents a challenge. Hospital visits to receive treatment and interaction with health care workers (HCW) represent potential contagious events. We aimed to determine SARS-CoV-2 infection rate among patients with cancer and HCW of a chemoradiotherapy unit localized in a center designated as a COVID-19 priority facility in Mexico City. We also determined the diagnostic performance of a clinical questionnaire (CQ) as a screening tool and anti-SARS-CoV-2 antibody seroconversion rate.

METHODS

HCW and patients with solid tumors attending the chemoradiotherapy unit signed informed consent. To determine SARS-CoV-2 infection rate prospectively, a nasopharyngeal swab for SARS-CoV-2 real-time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) was performed every 2 weeks in asymptomatics. An electronic CQ interrogating COVID-19-related symptoms was sent daily. Anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies were measured at baseline and at the end of the study period.

RESULTS

From June to September 2020, we included 130 asymptomatic participants, 44.6% HCW and 55.4% patients with cancer. During a median follow-up of 85 days, 634 nasopharyngeal swabs were performed. Average SARS-CoV-2 monthly incidence was 4.6% (3.15%-7.47%), and cumulative infection rate was 13.8% (18 of 130). Cases were mostly asymptomatic (66%), and no hospitalizations or deaths were recorded. The CQ as a screening tool provided a sensitivity of 27.7%, a positive predictive value of 26.3%, and a positive likelihood ratio of 12. SARS-CoV-2 IgG seroconversion rate was 27.7% among those with a positive RT-PCR.

CONCLUSION

Patients with cancer on treatment can have uncomplicated COVID-19 outcomes. Biweekly RT-qPCR testing detects asymptomatic infections, prevents transmission, and should be implemented in units to increase patient safety. CQ increase RT-qPCR diagnostic yield and may prioritize testing in resource-deprived settings. Post-infection IgG seroconversion is unreliable.

摘要

目的

在 COVID-19 大流行期间进行癌症治疗是一个挑战。到医院接受治疗以及与医护人员(HCW)的接触都可能导致疾病传播。我们旨在确定墨西哥城一个被指定为 COVID-19 重点设施的中心的化疗和放疗单位的癌症患者和 HCW 的 SARS-CoV-2 感染率。我们还确定了临床问卷(CQ)作为筛查工具的诊断性能和 SARS-CoV-2 抗体血清转化率。

方法

接受化疗和放疗的实体瘤患者和 HCW 签署了知情同意书。为了前瞻性地确定 SARS-CoV-2 感染率,对无症状者每两周进行一次 SARS-CoV-2 实时定量逆转录聚合酶链反应(RT-qPCR)鼻咽拭子检测。每天发送一份电子 CQ 来询问与 COVID-19 相关的症状。在基线和研究结束时测量 SARS-CoV-2 免疫球蛋白 G(IgG)抗体。

结果

从 2020 年 6 月到 9 月,我们纳入了 130 名无症状参与者,其中 44.6%是 HCW,55.4%是癌症患者。在中位随访 85 天期间,共进行了 634 次鼻咽拭子检测。平均每月 SARS-CoV-2 发病率为 4.6%(3.15%-7.47%),累计感染率为 13.8%(130 例中有 18 例)。病例大多为无症状(66%),没有住院或死亡记录。CQ 作为筛查工具的敏感性为 27.7%,阳性预测值为 26.3%,阳性似然比为 12。RT-PCR 阳性者 SARS-CoV-2 IgG 血清转化率为 27.7%。

结论

接受治疗的癌症患者可能会出现无症状 COVID-19 结果。每两周进行一次 RT-qPCR 检测可检测出无症状感染,可防止传播,应在单位实施以提高患者安全性。CQ 提高了 RT-qPCR 的诊断效能,并且可能优先在资源匮乏的环境中进行检测。感染后 IgG 血清转化率不可靠。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56bb/8667990/85949f3c3a41/go-7-go.21.00207-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验